Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Duloxetine Lilly
Duloxetine Lilly 30 mg hard gastro-resistant capsules Duloxetine Lilly 60 mg hard gastro-resistant capsules · Abschnitt 4.5 · PDF-Seite 8
HOS-133585 · Präparat HOS-097464
Medicinal products metabolised by CYP2D6: Duloxetine is a moderate inhibitor of CYP2D6. When
duloxetine was administered at a dose of 60 mg twice daily with a single dose of desipramine, a
CYP2D6 substrate, the AUC of desipramine increased 3-fold. The co-administration of duloxetine (40
mg twice daily) increases steady state AUC of tolterodine (2 mg twice daily) by 71 %, but does not
affect the pharmacokinetics of its active 5-hydroxyl metabolite and no dosage adjustment is
recommended. Caution is advised if Duloxetine Lilly is co-administered with medicinal products that
are predominantly metabolised by CYP2D6 (risperidone, tricyclic antidepressants [TCAs] such as
nortriptyline, amitriptyline, and imipramine) particularly if they have a narrow therapeutic index (such
as flecainide, propafenone and metoprolol).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nortriptyline (HOS-086245) propafenone (HOS-084530) tolterodine (HOS-087792) amitriptyline (HOS-085911) desipramine (HOS-086249) flecainide (HOS-086203) imipramine (HOS-085907) risperidone (HOS-086280) metoprolol (HOS-090094)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-09T15:33:00Z · SHA-256 61054d41822a6a0df108fca29fbebcc411cb952e97947b2c207af5bcdba0577a · Passage 7c7b25996f6a32c80fc33440a2dc74840f11c467175ef457a23ae83c3ba35d3b · Zeichen 2415–3237 im Abschnitt
Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)
Darunavir Viatris 75 mg film-coated tablets Darunavir Viatris 150 mg film-coated tablets Darunavir Viatris 300 mg film-coated tablets Darunavir Viatris 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 17–18
HOS-134507 · Präparat HOS-097580
17
INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS
Medicinal products by Interaction Geometric mean change Recommendations concerning co-
therapeutic areas (%) administration
Perphenazine Not studied. Darunavir is expected to A dose decrease may be needed for
Risperidone increase these antipsychotic plasma these drugs when co-administered
Thioridazine concentrations. with darunavir co-administered with
(CYP3A, CYP2D6 and/or P-gp low dose ritonavir.
inhibition)
Lurasidone Pimozide Concomitant administration of
Sertindole darunavir with low dose ritonavir
and lurasidone, pimozide or
sertindole is contraindicated (see
section 4.3).
β-BLOCKERS
Carvedilol Not studied. Darunavir is expected to Clinical monitoring is
Metoprolol increase these β-blocker plasma recommended when co-
Timolol concentrations. administering darunavir with β-
(CYP2D6 inhibition) blockers. A lower dose of the β-
blocker should be considered.
CALCIUM CHANNEL BLOCKERS
Amlodipine Not studied. Darunavir co-administered Clinical monitoring of therapeutic
Diltiazem with low dose ritonavir can be and adverse effects is recommended
Felodipine expected to increase the plasma when these medicines are
Nicardipine concentrations of calcium channel concomitantly administered with
Nifedipine blockers. darunavir with low dose ritonavir.
Verapamil (CYP3A and/or CYP2D6 inhibition)
CORTICOSTEROIDS
Corticosteroids primarily Fluticasone: in a clinical study where Concomitant use of darunavir with
metabolised by CYP3A ritonavir 100 mg capsules twice daily low dose ritonavir and
(including betamethasone, were co-administered with 50 μg corticosteroids (all routes of
budesonide, fluticasone, intranasal fluticasone propionate (4 administration) that are metabolised
mometasone, prednisone, times daily) for 7 days in healthy by CYP3A may increase the risk of
triamcinolone) subjects, fluticasone propionate plasma development of systemic
concentrations increased significantly, corticosteroid effects, including
whereas the intrinsic cortisol levels Cushing’s syndrome and adrenal
decreased by approximately 86% (90% suppression.
CI 82-89%). Greater effects may be
expected when fluticasone is inhaled. Co-administration with CYP3A-
Systemic corticosteroid effects metabolised corticosteroids is not
including Cushing’s syndrome and recommended unless the potential
adrenal suppression have been reported benefit to the patient outweighs the
in patients receiving ritonavir and risk, in which case patients should
inhaled or intranasally administered be monitored for systemic
fluticasone. The effects of high corticosteroid effects.
fluticasone systemic exposure on
ritonavir plasma levels are unknown. Alternative corticosteroids which
are less dependent on CYP3A
Other corticosteroids: interaction not metabolism e.g. beclomethasone
studied. Plasma concentrations of these should be considered, particularly
medicinal products may be increased for long term use.
when co-administered with darunavir
with low dose ritonavir, resulting in
reduced serum cortisol concentrations.
Dexamethasone (systemic) Not studied. Dexamethasone may Systemic dexamethasone should be
decrease plasma concentrations of used with caution when combined
darunavir. (CYP3A induction) with darunavir co-administered with
low dose ritonavir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) diltiazem (HOS-086288) triamcinolone (HOS-086333) nifedipine (HOS-086289) fluticasone (HOS-108914) nicardipine (HOS-090619) felodipine (HOS-108908) fluticasone propionate (HOS-086331) carvedilol (HOS-115322) risperidone (HOS-086280) amlodipine (HOS-086287) thioridazine (HOS-086281) perphenazine (HOS-116395) calcium (HOS-085615) betamethasone (HOS-090066) dexamethasone (HOS-084535) budesonide (HOS-086332) pimozide (HOS-085600) mometasone (HOS-114048) ritonavir (HOS-084521) beclomethasone (HOS-086334) lurasidone (HOS-086148) prednisone (HOS-084526) metoprolol (HOS-090094) timolol (HOS-090571) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage 4d699252eaa8e454816efcf834725c875d4dc8037df504e7418d309238a96785 · Zeichen 43154–48076 im Abschnitt
Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)
Darunavir Viatris 400 mg film-coated tablets Darunavir Viatris 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 59–60
HOS-134627 · Präparat HOS-097580
59
INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS
Medicinal products by Interaction Recommendations concerning co-
therapeutic areas Geometric mean change (%) administration
Perphenazine Not studied. Boosted darunavir is A dose decrease may be needed for
Risperidone expected to increase these these drugs when co-administered
Thioridazine antipsychotic plasma with boosted darunavir.
concentrations. (CYP3A, CYP2D6
and/or P-gp inhibition)
Lurasidone Concomitant administration of
Pimozide boosted darunavir and lurasidone,
Sertindole pimozide or sertindole is
contraindicated (see section 4.3).
β-BLOCKERS
Carvedilol Not studied. Boosted darunavir is Clinical monitoring is recommended
Metoprolol expected to increase these β-blocker when co-administering boosted
Timolol plasma concentrations. darunavir with β-blockers. A lower
(CYP2D6 inhibition) dose of the β-blocker should be
considered.
CALCIUM CHANNEL BLOCKERS
Amlodipine Not studied. Boosted darunavir can Clinical monitoring of therapeutic
Diltiazem be expected to increase the plasma and adverse effects is recommended
Felodipine concentrations of calcium channel when these medicines are
Nicardipine blockers. concomitantly administered with
Nifedipine (CYP3A and/or CYP2D6 boosted darunavir.
Verapamil inhibition)
CORTICOSTEROIDS
Corticosteroids primarily Fluticasone: in a clinical study Concomitant use of boosted
metabolised by CYP3A where ritonavir 100 mg capsules darunavir and corticosteroids (all
(including betamethasone, twice daily were co-administered routes of administration) that are
budesonide, fluticasone, with 50 μg intranasal fluticasone metabolised by CYP3A may increase
mometasone, prednisone, propionate (4 times daily) for 7 the risk of development of systemic
triamcinolone) days in healthy subjects, fluticasone corticosteroid effects, including
propionate plasma concentrations Cushing’s syndrome and adrenal
increased significantly, whereas the suppression.
intrinsic cortisol levels decreased
by approximately 86% (90% CI 82- Co-administration with CYP3A-
89%). Greater effects may be metabolised corticosteroids is not
expected when fluticasone is recommended unless the potential
inhaled. Systemic corticosteroid benefit to the patient outweighs the
effects including Cushing's risk, in which case patients should be
syndrome and adrenal suppression monitored for systemic corticosteroid
have been reported in patients effects.
receiving ritonavir and inhaled or
intranasally administered Alternative corticosteroids which are
fluticasone. The effects of high less dependent on CYP3A
fluticasone systemic exposure on metabolism
ritonavir plasma levels are e.g. beclomethasone should be
unknown. considered, particularly for long term
use.
Other corticosteroids: interaction
not studied. Plasma concentrations
of these medicinal products may be
increased when co-administered
with boosted darunavir, resulting in
reduced serum cortisol
concentrations.
Dexamethasone (systemic) Not studied. Dexamethasone may Systemic dexamethasone should be
decrease plasma concentrations of used with caution when combined
darunavir. with boosted darunavir.
(CYP3A induction)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) diltiazem (HOS-086288) triamcinolone (HOS-086333) nifedipine (HOS-086289) fluticasone (HOS-108914) nicardipine (HOS-090619) felodipine (HOS-108908) carvedilol (HOS-115322) risperidone (HOS-086280) amlodipine (HOS-086287) thioridazine (HOS-086281) perphenazine (HOS-116395) calcium (HOS-085615) betamethasone (HOS-090066) dexamethasone (HOS-084535) budesonide (HOS-086332) pimozide (HOS-085600) mometasone (HOS-114048) propionate (HOS-108915) ritonavir (HOS-084521) beclomethasone (HOS-086334) lurasidone (HOS-086148) prednisone (HOS-084526) metoprolol (HOS-090094) timolol (HOS-090571) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage 5be93392fc9daddc5a4bddcaf5177effda2055057fdf350b6c14c2d3c31e17fc · Zeichen 49576–54404 im Abschnitt
Wechselwirkungen · Besremi
Besremi 250 micrograms/0.5 mL solution for injection in pre-filled pen Besremi 500 micrograms/0.5 mL solution for injection in pre-filled pen · Abschnitt 4.5 · PDF-Seite 7
HOS-135525 · Präparat HOS-097722
Therefore, care should be taken when ropeginterferon alfa-2b is co-
substrates notably those having a narrow therapeutic margin such as theophylline or methadone.
e.g., vortioxetine, risperidone) combined
with ropeginterferon alfa-2b. Ropeginterferon alfa-2b may
and thus may increase the blood concentrations of these medicinal products.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methadone (HOS-086198) risperidone (HOS-086280) theophylline (HOS-085910) vortioxetine (HOS-128714)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-24T15:08:00Z · SHA-256 b821a9d463d0e9f05f3c2788ab2015a721e1b4a1ebc9433fe4d8072c0d2af2de · Passage 9f2660979b29f78e9ce6b3acc89b4a9ec8c8b3b051f0ba62cb4490801ecaa82c · Zeichen 1301–1710 im Abschnitt
Wechselwirkungen · Symtuza
Symtuza 800 mg/150 mg/200 mg/10 mg film-coated tablets Symtuza 675 mg/150 mg/200 mg/10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 13–14
HOS-138489 · Präparat HOS-098200
13
ANTIPSYCHOTICS/NEUROLEPTICS
Perphenazine Based on theoretical considerations Clinical monitoring is
Risperidone DRV/COBI is expected to increase recommended when
Thioridazine these neuroleptic plasma co-administering Symtuza with
concentrations. perphenazine, risperidone or
(CYP3A, CYP2D6 and/or P-gp thioridazine. For these
inhibition) neuroleptics, consider reducing
the dose of the neuroleptic upon
co-administration with Symtuza.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): risperidone (HOS-086280) thioridazine (HOS-086281) perphenazine (HOS-116395)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-16T11:21:00Z · SHA-256 542f840b29cc7afaff9940b20511550e8d35031b33d95efd774fd49f70f7819d · Passage b2135cf301bb2a290d08ffd07cf40e612721964164a091bff5b323d07f0ed9e3 · Zeichen 23766–24577 im Abschnitt
Wechselwirkungen · Inbrija
Inbrija 33 mg inhalation powder, hard capsules · Abschnitt 4.5 · PDF-Seite 5
HOS-142006 · Präparat HOS-098736
Dopamine D2 receptor antagonists (e.g. phenothiazines, butyrophenones, risperidone,
metoclopramide) and isoniazid may reduce the effectiveness of levodopa. Patients who are taking
these medicinal products should be monitored for worsening Parkinson’s symptoms (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dopamine (HOS-085948) risperidone (HOS-086280) metoclopramide (HOS-090626) isoniazid (HOS-088590)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-09T16:00:00Z · SHA-256 8efbaf885ca07144006263a202c7c665fe11b3f45faa6d3a3dd8a889b096ca73 · Passage f1649f88664919c76b7fce9d365e303ffdd9d5d2f50047872edf249ac7e24ce7 · Zeichen 566–844 im Abschnitt
Wechselwirkungen · Ozawade
Ozawade 4.5 mg film-coated tablets Ozawade 18 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-144415 · Präparat HOS-099178
QT-prolonging substances or known to increase the risk of repolarization disorders (e.g. haloperidol,
risperidone, erythromycine, clarithromycine, roxithromycine, loratadine, sildenafil)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): risperidone (HOS-086280) loratadine (HOS-086257) sildenafil (HOS-086162) haloperidol (HOS-085602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-06T11:36:00Z · SHA-256 6132349ff4302f19688e606b853696608a2e68d699ec2c7f66e494671825abac · Passage 3f86f3da4993a62c805a1e32578620abb2ea87e05f08f3b836230ea7e24a772c · Zeichen 608–794 im Abschnitt
Wechselwirkungen · Abiraterone Mylan
Abiraterone Mylan 500 mg film-coated tablets Abiraterone Mylan 1000 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6–7
HOS-146765 · Präparat HOS-099564
Caution is advised when administering with medicinal products activated by or metabolised by
CYP2D6, particularly with medicinal products that have a narrow therapeutic index. Dose reduction of
medicinal products with a narrow therapeutic index that are metabolised by CYP2D6 should be
considered. Examples of medicinal products metabolised by CYP2D6 include metoprolol, propranolol,
desipramine, venlafaxine, haloperidol, risperidone, propafenone, flecainide, codeine, oxycodone and
6
tramadol (the latter three medicinal products requiring CYP2D6 to form their active analgesic
metabolites).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): propafenone (HOS-084530) codeine (HOS-090544) desipramine (HOS-086249) flecainide (HOS-086203) oxycodone (HOS-109487) risperidone (HOS-086280) venlafaxine (HOS-086573) haloperidol (HOS-085602) propranolol (HOS-084529) metoprolol (HOS-090094) tramadol (HOS-112871)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-19T13:57:00Z · SHA-256 a224b8fadc2ad3e1b1af874d8687b8e3d6bb14c5f714b2308f5ba81c1b78da11 · Passage a9cc920d256817b14b1f63c2e0f3f180122c84999c9d524c0d853b81bd110d77 · Zeichen 1564–2206 im Abschnitt
Wechselwirkungen · Akeega
Akeega 50 mg/500 mg film-coated tablets Akeega 100 mg/500 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10
HOS-150309 · Präparat HOS-100288
Effects of niraparib or abiraterone acetate on other medicinal products
CYP2D6 substrates
Abiraterone is an inhibitor of CYP2D6. In a clinical study to determine the effects of abiraterone
acetate plus prednisone (AAP) on a single dose of the CYP2D6 substrate dextromethorphan, the
systemic exposure (AUC) of dextromethorphan was increased approximately 2.9-fold. The AUC24 for
dextrorphan, the active metabolite of dextromethorphan, increased approximately 33%. Dose
reduction of medicinal products with a narrow therapeutic index that are metabolised by CYP2D6
should be considered. Examples of medicinal products metabolised by CYP2D6 include metoprolol,
propranolol, desipramine, venlafaxine, haloperidol, risperidone, propafenone, flecainide, codeine,
oxycodone and tramadol.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): niraparib (HOS-136825) propafenone (HOS-084530) codeine (HOS-090544) acetate (HOS-088133) desipramine (HOS-086249) flecainide (HOS-086203) oxycodone (HOS-109487) risperidone (HOS-086280) venlafaxine (HOS-086573) haloperidol (HOS-085602) propranolol (HOS-084529) dextromethorphan (HOS-109265) prednisone (HOS-084526) metoprolol (HOS-090094) tramadol (HOS-112871)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-17T15:30:00Z · SHA-256 1bec7f3e5f18e4fe578c0f49b6a9128776963f703a1a9503180dea643f434459 · Passage 704800110d63379fb341b1ca9221e58b93483aec5c2142b646bcbfc2ed920ac5 · Zeichen 1171–1951 im Abschnitt
Wechselwirkungen · Onerji
Onerji (60 mg + 7.5 mg)/mL solution for infusion · Abschnitt 4.5 · PDF-Seite 8
HOS-152955 · Präparat HOS-100875
Dopamine D2 receptor antagonists (e.g. phenothiazines, butyrophenones, risperidone and
metoclopramide), and isoniazid, may reduce the therapeutic effect of levodopa. Monitor patients for
worsening of Parkinson’s disease symptoms.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dopamine (HOS-085948) risperidone (HOS-086280) metoclopramide (HOS-090626) isoniazid (HOS-088590)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-23T10:32:00Z · SHA-256 0a3b093da64a9acdd1634c12578cb8b735dccbd1f74b12bfa050312b0763b0d8 · Passage 033aa4f9bdbe97f1b9831ebd75e7a519879e9e1711a17839c159337cf1b9cbd0 · Zeichen 1831–2060 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.